Dec 21 (Reuters) - CSL Ltd (CSL) :
- CSL AND ARCTURUS THERAPEUTICS' ARCT-154 DEMONSTRATES NON-INFERIORITY TO ORIGINAL STRAIN AND SUPERIOR IMMUNOGENICITY TO OMICRON BA.4/5 VARIANT COMPARED TO FIRST-GENERATION MRNA VACCINE BOOSTER
- CSL LTD - ARCT-154 RESULTS WERE ACHIEVED WITH ONE-SIXTH DOSE OF COMIRNATY(®) (5 ΜG VERSUS 30 ΜG)
- CSL-ARCT-154 STUDY ONGOING,CONTINUES TO COLLECT SAFETY DATA,ASSESS DURABILITY OF IMMUNE RESPONSE IN PARTICIPANTS AT 3-,6-,12-MONTHS POST-VACCINATION
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$265.50 |
Change
1.550(0.59%) |
Mkt cap ! $128.5B | |||
| Open | High | Low | Value | Volume |
| $264.45 | $265.88 | $259.33 | $230.1M | 870.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 27 | $265.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $265.80 | 79 | 1 |
View Market Depth
| Last trade - 16.12pm 23/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |